Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery

Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery

This study is planned to medicate oral T3(Liothyronine)to the patients who are planned to have OPCAB(off- pump coronary bypass graft surgery. The aim of this study was to assess the effects of oral triiodothyronine (T3) therapy on postoperative thyroid hormone concentrations, hemodynamic variables and outcomes in patients undergoing OPCAB in a randomized, controlled trial.

Inclusion Criteria:

• Patients who are undergoing Off-pump coronary artery bypass graft

Exclusion Criteria:

• No normal sinus rhythm,
• History of thyroid disease
• Abnormal thyroid hormone
• Renal dysfunction
• Hepatic dysfunction
• LVEF <30%
• Recent MI
• Active infection 1~15